Table 2. Summary of Extracted Outcome Data.
| Source | OS | CNS DCR, median (IQR), % | CNS ORR, % | CNS PFS (cEFR), median, mo | CNS PFS (cFAS), median (IQR), mo | CNS DoR, median (IQR), mo | CNS TTR, median, mo | Best change in intracranial lesion size, median% | Complete response rate, % | Follow-up length, median, mo | CTCAE grade ≥3 adverse event rate, % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Devjak et al,40 2018 | NR | NR | 70 | NR | NR | NR | NR | NR | NR | NR | NR |
| Gadgeel et al,35 2017 | 70% At 1 y | 88 | NR | NR | NR | NR | NR | NR | NR | 7.1 | NR |
| Goss et al,34 2018 | NR | 92 (81-98) | 54 | Not reached (7 to not reached) | NR | Not reached | NR | −53 | 12 | 11 | 38 (cEFR) |
| Iuchi et al,30 2018 | NR | NR | NR | NR | NR | 13.8 | NR | NR | NR | NR | NR |
| Kim et al,32 2017 | NR | NR | 81.3 | Not reached | Not reached | Not reached | NR | NR | NR | NR | NR |
| Mu et al,36 2018 | NR | 80 | 53.3 | Not reached | NR | NR | 1.3 | −40 | 23 | 6.5 | NR |
| Park et al,41 2018 | Not reached | 100 | NR | Not reached | Not reached | NR | NR | NR | NR | NR | NR |
| Peled et al,33 2018 | NR | NR | 75 | Not reached | NR | NR | NR | NR | NR | 10 | NR |
| Reungwetwattana et al,24 2018 | NR | 95 (77-100) | 91 | NR | Not reached (16.5 to not reached) | 15.2 (4.1 To not reached) | 1.5 | −64 | 23 | 12.4 | 33 |
| Sonoda et al,37 2017 | NR | NR | 67 | NR | NR | NR | NR | NR | NR | NR | 30 |
| Wu et al,23 2018 | NR | 93 (81-98) | 70 | NR | 11.7 (10 To not reached) | 8.9 (4.3 To not reached) | 1.5 | −43 | 7 | 5.5 | 19 |
| Xie et al,38 2019 | 16.2 mo | NR | 32.3 | NR | NR | NR | NR | NR | 10 | 8.5 | NR |
| Xing et al,19 2018 | NR | 97 | 71.9 | 10.9 (6.1 To not reached) | NR | 8.3 (5.8 To not reached) | NR | NR | NR | NR | 39.5 |
| Xing et al,39 2019 | Not reached | 80 (57-100) | 53.3 | Not reached | NR | NR | 1.3 | −40 | 20 | 6.5 | 22.7 |
| Zhou et al,31 2017 | NR | 91 (73-93) | 70 | Not reached (9.4 to not reached) | Not reached | 11.1 (8.2 To not reached) | NR | NR | NR | 8.2 | NR |
Abbreviations: cEFR, central nervous system evaluable for response set; cFAS, central nervous system full analysis set; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events (version 3.0); DCR, disease control rate; DoR, duration of response; IQR, interquartile range; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TTR, time to response.